Case Report

Massive hemothorax following administration of intrapleural streptokinase

Feng Yih Chai, Yeh Chunn Kuan

Abstract:
The administration of intrapleural streptokinase (IPSK) is widely practiced in the management of loculated empyema thoracis. To our knowledge, there have been only 4 cases of hemorrhagic complications attributed to the administration of IPSK reported in the literature. In this article, we report a case of a 17-year-old girl who received IPSK and developed shock, anemia, coagulopathy and massive hemothorax. Our discussion focuses on the hemorrhagic complication of chest tube insertion and the role of IPSK in blood clot lysis and inhibition of local hemostasis.

Key words:
Coagulopathy, complications, hemothorax, streptokinase, thoracic empyema

Intrapleural streptokinase (IPSK) administration in loculated empyema thoracis may improve its drainage by breaking down the fibrinous septations.[1,2] Despite contradicting data on safety and efficacy of IPSK, it is practiced widely.[2,3] Here, we report a case of severe intrapleural hemorrhage after the administration of IPSK and discuss other possible causes of the bleeding.

Case Report

A 17-year-old girl was admitted with 3 weeks of fever, productive cough and right pleuritic chest pain. On presentation, her respiratory rate was 28 breaths/minute, blood pressure was 87/52 mm Hg, heart rate was 140 beats/minute, temperature was 39.5°C and oxygen saturation was 96% in room air. There were crepitations bilaterally and reduced breath sounds at the right lower hemithorax with stony dullness on percussion. Her investigations showed that her hemoglobin was 9.0 g/dL, platelet count was 386,000/μL, white blood cell count was 12,140/μL (predominantly neutrophils) and coagulation profile was normal. Her chest radiograph [Figure 1] showed a large right loculated pleural effusion. A 28-French chest tube was inserted, and a total of 1.2 L of pus was drained. She was diagnosed with right loculated empyema thoracis and started on intravenous co-amoxiclav 1.2 g three times a day. Two days later, her vital signs returned to normal.

On day 3 of admission, the chest tube was replaced because it was blocked. However, chest tube drainage remained poor despite persistent pleural effusion on chest radiograph [Figure 2].
When regular flushing with normal saline failed to improve chest tube drainage, the patient was started on intrapleural streptokinase 250,000 units, 12 hourly.

After 3 doses of IPSK, the patient complained of palpitations, sweating and giddiness and had a respiratory rate of 25 breaths/minute, blood pressure of 70/50 mm Hg, pulse rate of 140 beats/minute and temperature of 38.5°C. Her blood investigations showed that her hemoglobin had dropped to 6.5 g/dL with a platelet count of 209,000/μL and white cell count of 18,600/μL. Her International Normalized Ratio was 1.5, but her activated partial thromboplastin time was normal. Chest radiograph was repeated [Figure 3], which showed that her right hemothorax was completely opaque, but her chest tube continued to drain only 100 mL of sanguineous fluid daily. She was diagnosed with a right massive hemothorax.

An immediate thoracic surgical consult was sought. However, the patient was too unstable for transport to the nearest cardiothoracic surgical center, which was 250 km away. We were advised to promptly resuscitate and stabilize the patient at our intensive care unit. Her chest tube was blocked and was replaced again. The new chest tube drained 1.1 L of altered blood over the next 2 days. A total of 7 units of packed red blood cells were transfused to restore her hemodynamic status. Her hemoglobin level was 9.6 g/dL post-transfusion, and her blood cells were transfused to restore her hemodynamic status. After 14 days of intensive care, she was then transferred to the cardiothoracic center, where she underwent right lung decortications and recovered uneventfully.

Discussion

Despite advancement in technology and the availability of more efficacious antibiotics, empyema thoracis still requires drainage. Our patient had her chest tube inserted unassisted by imaging within 24 hours of admission and drained 1.2 L of pus. Ideally, ultrasonography or computed tomography prior to chest tube insertion should be used to locate the most suitable chest tube entry site for drainage of loculated empyema. It can prevent complications and may improve outcome.[4]

Hemorrhagic complication after IPSK administration is rare. To our knowledge, there have been only 4 cases of hemorrhagic complications attributed to the administration of IPSK reported in the literature.[3,5,6] Our patient was given 3 doses of IPSK (250,000 IU, 12 hourly) before she developed anemia, shock and coagulopathy. Her condition could have resulted from massive intrapleural hemorrhage due to traumatic chest tube insertion. On the other hand, in the presence of leukocytosis and fever, sepsis could have complicated her shock and coagulopathy.

The usage of IPSK as intrapleural fibrinolytic therapy is debatable. Its usage is considered safe and has not been shown to activate systemic fibrinolytic activity.[7] However, given the immunogenicity of streptokinase and its inability to reduce pus viscosity, there has been increasing interest in tissue plasminogen activator (tPA) and recombinant human deoxyribonuclease (DNase) as better alternatives to facilitate drainage of empyema thoracis. tPA induces fibrinolysis by preferentially activating plasminogen bound to fibrin and is less immunogenic, whereas DNase reduces pus viscosity by fragmenting free uncoiled deoxyribonucleic acid found in pus.[8,9] A multicentered randomized trial by Rahman et al. has shown that combination of tPA and DNase was significantly superior to using either tPA or DNase alone in improving pleural fluid drainage.[9]

The complication rate of chest tube insertion is reported as high as 30%, with hemorrhagic complication ranging from 3.0% to 7.8%.[10] Hemorrhage from chest tube insertion can be caused by injured intercostal vessels or by lung parenchyma. Our patient’s second chest tube insertion was uneventful. It was conducted by an experienced medical officer, who encountered minimal external blood loss. A subsequent computed tomography of the thorax showed that the chest tube was placed appropriately without causing any active bleeding from the chest wall. However, small lung parenchymal injury could not be ruled out on the basis of the scan. The lung parenchyma could be injured during the instrumentation and later concealed by blood clots. Consequently, no major bleeding was seen through the chest tube drainage.

Temes et al. reported a case of a patient who developed hemothorax following administration of IPSK for empyema thoracis.[11] During the emergency thoracotomy, the hemorrhage was found to have originated from a rib fracture sustained 1 month prior to administration of IPSK. Streptokinase is a potent fibrinolytic agent. It binds and activates human plasminogen to produce plasmin. Subsequently, plasmin breaks down fibrin, which is a major constituent of a blood clot, and dissolves the clot. Therefore, it is possible that the administered IPSK had dissolved the formed blood clot at our patient’s traumatized lung parenchyma, inhibited local hemostasis and caused hemorrhage.

In conclusion, administration of IPSK may cause rare but life-threatening intrapleural hemorrhage. Its potent fibrinolytic activity lyses not only the fibrinous septations in loculated empyema thoracis but also possibly the blood clot covering a traumatized area and inhibits local hemostasis.

References

1. Maskell NA, Davies CW, Nunn AJ, Hedley EL, Gleeson FV, Miller R, et al. UK controlled trial of intrapleural streptokinase for pleural infection. N Engl J Med 2005;352:865-74.
2. Temes RT, Follis F, Kessler RM, Pett SB Jr, Wernly JA. Intrapleural fibrinolytics in management of empyema thoracis. Chest
3. Cameron RJ, Davies HR. Intra-pleural fibrinolytic therapy versus conservative management in the treatment of adult parapneumonic effusions and empyema. Cochrane Database Syst Rev 2008;2:CD002312.

4. Davies CW, Gleson FV, Davies RJ. BTS guidelines for the management of pleural infection. Thorax 2003;58:iii18-28.

5. Laisaar T, Püttepp E, Laisaar V. Early administration of intrapleural streptokinase in the treatment of multiloculated pleural effusions and pleural empyemas. Thorac Cardiovasc Surg 1996;44:252-6.

6. Godley PJ, Bell RC. Major haemothorax following administration of intrapleural streptokinase. Chest 1984;86:486-7.

7. Davies CW, Lok S, Davies RJ. The systemic fibrinolytic activity of intrapleural streptokinase. Am J Respir Crit Care Med 1998;157:328-30.

8. Simpson G, Roomes D, Heron M. Effects of streptokinase and deoxyribonuclease on viscosity of human surgical and empyema pus. Chest 2000;117:1728-33.

9. Rahman NM, Maskell N, Davies CW, West A, Teoh R, Arnold A, et al. Primary result of the second multicentre intrapleural sepsis (MIST2) trial; randomized trial of intrapleural tPA and DNase in pleural infection. Thorax 2009;64:A1.

10. Ball CG, Lord J, Laupland KB, Gmora S, Mulloy RH, Ng AK, et al. Chest tube complications: How well are we training our residents? Can J Surg 2007;50:450-8.

How to cite this article: Chai FY, Kuan YC. Massive hemothorax following administration of intrapleural streptokinase. Ann Thorac Med 2011;6:149-51.

Source of Support: Nil, Conflict of Interest: None declared.